{"schema_version":"secwatch.filing_event.v1","accession":"0001655759-25-000103","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2025-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.224580+00:00","generated_at":"2026-05-19T08:29:11.157125+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Arvinas reports preclinical data for PROTAC BCL6 degrader ARV-393 at EHA 2025","bullets":["Single-agent ARV-393 reduced tumor burden in peripheral blood, bone marrow, and spleen in nTFHL-AI PDX model from a post-chemo relapsed patient.","ARV-393 monotherapy achieved ≥95% tumor growth inhibition (TGI) in two PDX models of transformed follicular lymphoma (tFL).","Combinations with 5 small molecule inhibitors (tazemetostat, palbociclib, everolimus, acalabrutinib, venetoclax) enhanced TGI; regressions seen with 4 of 5.","Phase 1 study (NCT06393738) enrolling relapsed/refractory non-Hodgkin lymphoma patients, including DLBCL and AITL.","Data suggest broad utility across NHL subtypes and support chemotherapy-free combination strategies."],"urls":{"canonical":"https://secwatch.observer/filing/0001655759-25-000103","json":"https://secwatch.observer/filing/0001655759-25-000103.json","markdown":"https://secwatch.observer/filing/0001655759-25-000103.md","text":"https://secwatch.observer/filing/0001655759-25-000103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000165575925000103/0001655759-25-000103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000165575925000103/arvn-20250613.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T08:29:11.157125+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}